Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Recruiting

Phase 2

Losartan with ModulatorTargeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Sponsor:

University of Kansas Medical Center

Code:

NCT06364176

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Losartan

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by University of Kansas Medical Center on 2024-06-05.